CellMade was established in 2007 by Ronald Bronsaer with support from Sofimac Partners and a group of private investors. In 2009, it established an agreement with DSM RESOLVE – R&D solutions , part of the highly regarded and long-established DSM group, based in the Netherlands. DSM RESOLVE provides a broad spectrum of high-end analytical, technical and safety services based on years of experience in the chemical arena. The relationship between CellMade and DSM RESOLVE combines CellMade’s specialist CellInsight™ technology and expertise for supporting inflammation drug and biomarker discovery, with DSM RESOLVE’s state-of-the-art capability in lipid profiling using mass spectrometry. The combined technology delivers real-time, reliable evaluations of the effects of new small molecule or biological drugs on inflammatory processes. In July 2010, CellMade closed an investment round of €1.7M from four main investors: Sofimac Partners, Dutch regional VC funds Limburg Ventures and Nedermaas High Tech ventures, and DSM Resolve B.V. This latest investment is enabling the company to develop further applications of its CellInsight™ platform and to add to its growing intellectual property portfolio of inflammatory biomarkers.